Roivant Sciences (ROIV) Cost of Revenue (2020 - 2026)

Roivant Sciences (ROIV) has reported Cost of Revenue for 7 consecutive years, with $284000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 84.42% year-over-year to $284000.0; the trailing twelve-month figure through Jun 2026 stood at $1.5 million (up 15.84% YoY), and the FY2026 full-year result was $1.3 million, up 41.05% from the prior year.
• Cost of Revenue slipped to $284000.0 in Q2 2026 per ROIV's latest filing, from $965000.0 in the prior quarter.
• Across five years, Cost of Revenue topped out at $9.0 million in Q4 2022 and bottomed at $111000.0 in Q3 2025.
• Historically, Cost of Revenue has averaged $1.8 million across 5 years, with a median of $706000.0 in 2024.
• The sharpest annual moves came in 2023 and 2024: Cost of Revenue surged 144.15% in 2023, then tumbled 94.95% in 2024.
• Over 5 years, Cost of Revenue stood at $9.0 million in 2022, then sank by 84.33% to $1.4 million in 2023, then slumped by 49.68% to $706000.0 in 2024, then jumped by 36.69% to $965000.0 in 2025, then sank by 70.57% to $284000.0 in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $284000.0, $965000.0, and $111000.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.